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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.12.002CONTEXT AND OBJECTIVE: By using molecular markers, it is possible to gain information on both the classi-
fication and etiopathogenesis of chronic myeloproliferative neoplasias (MPN).
METHODS: In a group of 27 Mexican mestizo patients with MPNs, we studied seven molecular markers: the
BCR/ABL1 fusion gene, the JAK2 V617F mutation, the JAK2 exon 12 mutations, the MPL W515L mutation,
the MPL W515K mutation, and the calreticulin (CALR) exon 9 deletion or insertion. Patients with the BCR/
ABL1 fusion gene were excluded. We studied 14 patients with essential thrombocythemia (ET), eight with poly-
cythemia vera (PV), four with primary myelofibrosis (MF), and one with undifferentiated MPN.
RESULTS: We found twelve individuals with the JAK2 V617F mutation; five of them had been clinically clas-
sified as PV, five as ET, and one as MF. One patient with the MPL W515L was identified with a clinical picture of
ET. Five patients with the CALR mutation were identified, four ET and one MF. No individuals with either the
MPL W515K mutation or the JAK2 exon 12 mutations were identified. The most consistent relationship was that
between PV and the JAK2 V617F mutation (p = .01).
CONCLUSIONS: Despite its small size, the study shows much less prevalence of JAK2 mutation in PV, ET and
MF, which does not match international data.
KEYWORDS: Myeloproliferative neoplasms; Molecular markers; JAK2 V617F mutation; JAK2 exon 12 mutation; MPL W515L
mutation; MPL W515K mutation; CAL-R mutationsINTRODUCTION
hronic myeloproliferative neoplasias (MPN)
are clonal hematopoietic stem cell disorders
characterized by proliferation of myeloid cell
lineages in the bone marrow and increased numbers
of mature and immature cells in the blood.[1,2]
MPNs include polycythemia vera (PV), essential
thrombocythemia (ET), idiopathic myeloﬁbrosis
(MF) and chronic myelogenous leukemia (CML),
plus rarer subtypes such as chronic neutrophilic leu-kemia, hypereosinophilic syndrome, and chronic
eosinophilic leukemia. These diseases overlap with
myelodysplastic/myeloproliferative diseases such as
atypical CML and chronic myelomonocytic leukemia,
in which proliferation is accompanied by dysplastic
features or ineffective hematopoiesis in other lin-
eages.[3,4] Although there are stringent diagnostic
criteria for MPN subtypes, precise categorization
remains a subject of debate and, furthermore, it can
be difﬁcult to differentiate some cases from reactive
disorders. CML is characterized by a pathognomonicarter 2015
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molecular marker, the BCR-ABL1 fusion, and the
primary abnormalities driving excess proliferation in
most other cases have been obscure. Several lines of
evidence have implicated aberrant protein kinase
(PTK) signaling as the root cause of several
MPNs.[3,4]
Mutations in JAK2, MPL and calreticulin
(CALR) are highly relevant to the Philadelphia chro-
mosome (Ph1)-negative myeloproliferative neoplasms.
In 2005, the ﬁrst recurrent molecular abnormality was
described, consisting of a G > T point mutation in
JAK2 (JAK2{NM_004972.2}:c.2343G > T) and
resulting in a valine to phenylalanine substitution at
residue 617 (V617F).[5] Subsequently, the discovery
of mutations in MPL, represented by a W > L
(MPL{NM_005373.2}:c.1544G > T) or W > K
(MPL:c.1543_1544TG > AA) shift at codon 515,
and of variable molecular abnormalities (point muta-
tion, insertion, deletion) in JAK2 exon 12 was also
reported.[6] Almost all patients with PV have a
somatic genetic defect in JAK2 that is represented
by the V617F allele in 90–95% of cases and by abnor-
malities in exon 12 in roughly 2%, while they are
spared by MPL mutations. On the other hand, only
60% of patients with ET or MF harbor the JAK2
V617F mutation and 3–7% exhibit the MPL
W515L/K mutation.[7] Recently, somatic mutations
in the gene CALR, encoding calreticulin, have been
found in most patients with ET or MF with nonmu-
tated JAK2 and MPL. Mutant CALR is a result of
frameshift mutations, caused by exon 9 deletions or
insertions; type-1, 52-bp deletion (p.L367fs*46), and
type-2, 5-bp TTGTC insertion (p.K385fs*47) vari-
ants constitute more than 80% of these mutations.[8]
With these molecular markers, it is possible to
gain information on both the classiﬁcation and etio-
pathogenesis of some MPNs. In a group of Mexican
mestizo patients with MPNs, we studied seven molec-
ular markers of the MPNs: the BCR/ABL1 fusion
gene, the JAK2 V617F mutation, the JAK2 exon
12 mutations, the MPL W515L mutation, the
MPL W515K mutation, the type-1 CALR mutation
and the type-2 CALR mutation. We report here the
results of these investigations.MATERIAL AND METHODS
Patients
Patients with hematological malignancies who pre-
sented at the Centro de Hematología y Medicina
Interna de Puebla after August 2005 were prospec-
tively accrued in the study along with DNA samples
from our bank. The diagnoses and classiﬁcation ofHematol Oncol Stem Cell Ther 8(1) First Quarter 2015leukemia were done according to conventional
criteria[1,9,10]; patients were studied, treated and fol-
lowed up by one of the authors of this study (GJRA).
Informed consent was obtained from all patients. The
deﬁnition of mestizo employed in this study covers
individuals born in Latin America who had both
Amerindian and white ancestors.[11] Included in
the study were 150 healthy blood donors as the con-
trol group.
Molecular biology studies
Analysis of the BCR/ABL1 fusion gene
The BCR-ABL1 speciﬁc transcripts were detected by
RT-PCR, as previously described.[12] Brieﬂy, total
RNA, puriﬁed from 1 ml peripheral blood, was
reverse transcribed by standard methods. One ﬁfth
of the cDNA was ampliﬁed for 40 cycles (pre-cycle:
1 min 95 C; cycles: 15 s 94 C, 20 s 60 C, 20 s
72 C; post-cycle: 2 min 72 C) in 50 ll ﬁnal volume
(2 U Taq, 1.5 mM MgCl2, 0.4 lM each primer:
TCGTGTGTGAAACTCCAGAC, CCATCCCC
CATTGTGATTAT, and ACTGCCCGGTTGTC
GTGT). Ten microliters of ampliﬁed material were
analyzed on 4.5% PAGE. Negative PCR results were
validated by detection of ABL1 transcripts (primers:
CCATCCCCCATTGTGATTAT and TAGCA
TCTGACTTTGAGCCT).
Analysis of the JAK2 V617F mutation
An ampliﬁcation refractory mutation system (ARMS)
method was used according to Baxter et al.[13]
Brieﬂy, genomic DNA was isolated from peripheral
blood leukocytes according to standard procedures.
In a multiplex format, the mutation was detected with
the help of allele speciﬁc primers (203 bp) and the
complete exon 14 was ampliﬁed as an internal ampli-
ﬁcation control (364 bp), taking care not to exceed
0.05 lg of DNA per 50 ll ampliﬁcation reaction.
Ampliﬁcation products were analyzed after electro-
phoresis on 4.5% polyacrylamide gels.
Analysis of the MPL W5151K/L mutation
For the detection of MPL mutations in separate reac-
tions, ARMS primers were designed (W515 speciﬁc
primer GGCCTGCTGCTGCTGAGATG, L515
speciﬁc primer GGCCTGCTGCTGCTGAGATT,
K515 speciﬁc primer GGCCTGCTGCTGCTGAG
GAA, and the common primer GGGCGGTATAG
TGGGCGTGT) according to Newton et al.[14]
with the introduction of extra destabilizing mis-
matches at position – 2 to increase speciﬁcity. Brieﬂy,
10–250 ng of DNA was ampliﬁed (pre-cycle: 2 min
at 94 C; 35 cycles: 20 s at 94 C, 30 s at 64 C,17
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30 s at 72 C; ﬁnal extension: 2 min at 72 C) in
presence of 1 lM speciﬁc and common primers
(2 U Taq DNA polymerase, 1.5 mM MgCl2).
Ampliﬁcation products were analyzed by PAGE in
4.5% gels.
Analysis of the JAK2 exon 12 mutation
JAK2 exon 12 mutations were studied as outlined by
Scott et al.[15] All patient DNAs were screened by
allele speciﬁc PCR for K539L, N542-E543del,
F537-K539delinsL, and H538QK539L mutations.
In addition, the entire exon 12 was sequenced in
patients with PV or primary erythrocytosis.
Analysis of the CALR type 1 and type 2 mutations
Analysis of CALR insertions and deletions was per-
formed by fragment analysis essentially as described
by Nangalia et al.[16] Samples were tested by ampli-
fying the 30 part of exon 9 with labeled primers CAL-
Re9F (CCTGCAGGCAGCAGAGAAAC) and
CALRe9P (6FAM-ACAGAGACATTATTTGGC
GCG). Ampliﬁcation products were submitted to
capillary electrophoresis (ABI 3130, Applied Biosys-
tems de México, SA de CV, Mexico City) and signals
were analyzed with the help of GeneMapper ID v3.2
(Applied Biosystems de México, SA de CV, Mexico
City).RESULTS
A total of 27 mestizo individuals with chronic myelo-
proliferative neoplasias were studied: 14 with ET,
eight with PV, four with MF, and one with undiffer-
entiated MPN. Patients with the BCR-ABL1 fusion
gene were classiﬁed as CML and excluded from the
study. Twelve individuals with the JAK2 V617F
mutation were found; ﬁve of them had been clinicallyCALR mutations in Mexican patients with chronic myeloproliferative neop
N = undifferentiated myeloproliferative neoplasia.
n JAK2





27 12 0classiﬁed as PV, ﬁve as ET, one as MF, and one as
undifferentiated MPN. One patient with MPL
W515L was identiﬁed with a clinical picture of ET.
Five individuals with the CALR mutation were iden-
tiﬁed: four with ET and one with MF. On the other
hand, of the 14 individuals with ET, ﬁve (36%) had
the JAK2 V617F mutation, one (7%) had the MPL
W515L mutation, and four (29%) had the CALR
mutation. Of the eight individuals with PV, ﬁve
(62%) displayed the JAK2 V617F mutation, whereas
of the four patients with MF, one had the JAK2
V617F mutation and one had the CALR mutation.
Accordingly, the most consistent relationship was that
between PV and the JAK2 V617F mutation
(p = .01). Table 1 shows the prevalence of these
molecular markers in each category of the Ph1-nega-
tive MPN. CALR was the second most frequently
mutated gene in MPN, as previously shown.[17]
There was no signiﬁcant difference in gender, age or
platelet counts or between patients with mutant
CALR and JAK2 V617F. A lower white blood cell
count was observed when comparing CALR versus
JAK2 V617 mutated and triple negative MPN
(p = 0.011). Among all patients, four (14.2%) had a
thrombotic episode. JAK2 V617F mutated patients
had signiﬁcantly higher frequencies of thrombosis
(p = 0.028).DISCUSSION
Our understanding of the genetic basis of MPN neo-
plasms began in 2005, when the JAK2 (V617F)
mutation was identiﬁed in PV, ET and MF. JAK2
exon 12 and MPL exon 10 mutations were then
detected in subsets of patients, and subclonal driver
mutations in other genes were found to be associated
with disease progression. Recently, somatic mutationslasias (MPN). ET = essential thrombocythemia; PV = polycythemia vera;
MPL CALR
W515L W515K del52 ins5
1 0 3 1
0 0 0 0
0 0 0 1
0 0 0 0
1 0 3 2
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Table 2. JAK2, MPL and CALR mutations in patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasias (MPN). ET = essential thrombocythemia;
PV = polycythemia vera; MF = myelofibrosis; NI: Not investigated; NS: Not specified.
MPN References JAK2 MPL CALR
V617F Exon 12mutations W515L W515K del52 (Type 1) Ins5 (Type 2)
ET Tefferi et al.19 57% NS 3% NI 16% 14%
Chen et al.20 63.9% NS 2.7% 0% 12.2% 6.1%
Rumi et al.21 62% 0% 4% 11.3% 9.3%
Quiao et al.22 45.5% NI 0.9% 31.1%
Wu et al. 21 56.3 0% 3.8% 1.3% 25%
Akpinar et al.24 43.9% NI 0% NI
This study 36% 0% 7.1% 0% 21% 7%
PV Quiao et al.22 91.9% 2.7% NI NI NS NS
Wu et al. 23 82.5% 12.5% 0% 0%
This study 62.5% 0% 0% 0% 0%
MF Quiao et al. 22 60.6% 0% 0% 12.1%
Xia et al. 25 50.0% 0% 6.7% 0% NI
Tefferi et al.19 54.7% NI NI NI 21% 2.8%
Akpinar et al. 6 54.5% NI 33.3% NI NI
This study 25% 0% 0% 0% 25%
CLASSIFICATION OF MYLEOPROLIFERATIVE NEOPLASMS original research reportin the gene CALR, encoding calreticulin, have been
found in most patients with ET or MF with nonmu-
tated JAK2 and MPL. The JAK-STAT pathway
appears to be activated in all MPN, regardless of
founding driver mutations. These latter, however,
have different effects on clinical course and outcomes.
Thus, evaluation of JAK2, MPL, and CALR muta-
tion status is important not only for diagnosis but also
for prognostication. These genetic data should now
also be considered in designing clinical trials.[17] It
has been previously described that:
(a) In PV, the JAK2 (V617F) mutation presents in
about 95%, whereas the JAK2 exon 12 mutation pre-
sents in 5% of patients.
(b) In ET, the JAK2 (V617F) mutation presents in
about 60%, the MPL exon 10 mutations in 5% and
the CALR exon 9 mutations in 20% of patients.
(c) In MF, the JAK2 (V617F) mutation presents in
about 60%, the MPL exon 10 mutations in 5% and
the CALR exon 9 mutations in 20% of patients.
Despite the small size of the study, we have found
much less prevalence of JAK2 mutation in PV, ET
and MF, which does not match international data
The data also conﬁrm our previous observation aboutHematol Oncol Stem Cell Ther 8(1) First Quarter 2015the diminished prevalence of PV in Mexico as
compared with the prevalence of other MPN in our
country
_
[2,10] As previously described in other parts
of the world,[17] in Mexico, the JAK2 (V617F)
mutation is the most frequent gene mutation in
MPN, followed by the CALR exon 9 mutation, with
the MPL and the JAK2 exon 12 mutations being less
frequent These data also support the idea that in the
study of MPN it is very important to look for the
mutation proﬁle of the three genes JAK2, MPL and
CALR, since the identiﬁcation of one of these molec-
ular markers could be considered enough to consoli-
date a diagnosis of MPN On the other hand, these
markers are also useful in the follow-up treatment
of some of these diseases, such as the result of bone
marrow transplantation in patients with MPNs who
display one of these molecular markers, and which
can disappear as a result of treatment
_
[10,18] The
Table 2 shows comparative data of our ﬁndings with
other papers
_
[19–25]Although we extracted the data
from a small-sized patient cohort, this is the ﬁrst
report of CALR mutations in Mexican MPN patients
JAK2 V617F and CALR have been associated
with different clinical features in MPN patients.
Previous publications reported a higher platelet count19
20
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and lower leukocyte and hemoglobin values in CALR
mutant patients compared to those with JAK2
V617F or MPL mutations.[21–27] In our cohort,
we were not able to ﬁnd any signiﬁcant difference
for hemoglobin or platelet count, but signiﬁcantly
lower white cell counts for CALR mutated patients
were noted (p = 0.011). It has been clearly established
that JAK2V617F mutation represents a strong inde-
pendent risk factor for thrombosis and, as previously
reported, the incidence of thrombotic events in our
study was signiﬁcantly higher in JAK2 mutated cases
when compared to CALR mutated and triple-negative
patients (p = 0.028).[27,28] Contrary to other stud-
ies, we did not ﬁnd a male predilection or a lower
hemoglobin level in CALR-mutated patients, but
these inconsistent ﬁndings are probably the result of
an insufﬁcient case number in our cohort.
Therapeutic uses have been derived from the iden-
tiﬁcation of the molecular markers of MPN. Speciﬁc
inhibitors of JAK2 have been developed and employed
in the treatment of JAK2-mutated MPN.[29] These
inhibitors have also been shown to be useful in the
treatment of other non JAK2-mutated neoplasias suchas other leukemias,[30] and also as anti-cytokines
treatment of non-malignant inﬂammatory condi-
tions[31] and graft versus host disease.[32] It is thus
possible that speciﬁc inhibitors of MPL or CALR
may eventually ﬁnd a therapeutic use.
A revision of the World Health Organization
(WHO) classiﬁcation of the MPN is ongoing; its
classiﬁcation will hopefully take into account the
recent genetic advances in this ﬁeld. At present, the
clinical phenotype of the MPN (ET, PV or MF) con-
tinues to be important. Because of their clinical rele-
vance, genetic markers should be properly
considered both in clinical decision-making and in
the design of clinical trials.[17] In this small study,
we found much less prevalence of JAK2 mutation in
PV, ET and MF, which does not match international
data. Additional studies are needed to either ratify or
rectify these ﬁndings.CONFLICT OF INTEREST
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